David Miller
Chief Financial Officer
Replay available
Champions Oncology (NASDAQ:CSBR) Q4 2020 earnings call, held 2020-07-27. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/champions-oncology-inc-csbr-q4-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Thank you.
0:01 Your event playback will now begin. Greetings, and welcome to Champions Oncology's fourth quarter fiscal year 2019 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ronnie Morris, CEO. Please go ahead.
0:40 Good afternoon. I am Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial Officer. Thank you for joining us for our quarterly earnings call. Before we begin, I will remind you that we'll be making forward looking statements during and that actual results could differ materially from what is described in those statements. Additional information on factors that could cause results to differ is available in our Forms 10Q and Form 10K. A reconciliation of non-GAAP financial measures that may be discussed during the call to GAAP financial measures is available in the earnings release. Overall, we had another good quarter, and the theme for this call will be similar to prior calls as we continue to execute on our strategies and update you on the results.
1:26 We had a record-breaking quarter with revenue reaching $9 million for the first time. Excluding stock-based compensation and depreciation, we recorded net income of approximately $900,000. Bookings in both our core products and new product launches continued to strengthen, setting the stage for continued revenue expansion in the quarters ahead. As most of you know, we launched our regulatory clinical flow cytometry services a couple of quarters ago, and to date we have not yet signed our first study. However, our pipeline of opportunities in GCLP flow is growing and we are encouraged by the level of interest in the early stages of this product launch. We have had multiple pharma companies give us positive feedback after inspecting and auditing our facilities and as a result have added us to their preferred vendor list.
2:18 This will enable us to bid on their future regulatory flow cytometry opportunities. While we understand there is anticipation for immediate results, we reiterate that we are building an impressive pipeline of opportunities, we are increasing our flow sales force, and we are confident it will lead to signed studies in the coming months. We have also realized an unintended positive benefit while we have been aggressively marketing our GLP flow cytometry services, which highlights our state-of-the-art equipment and operational excellence. As a result of these efforts, we have seen an approximate 40% increase in our preclinical flow cytometry services, leading to larger studies in our core preclinical business.
3:03 We look forward to additional growth in both preclinical and clinical flow over the coming quarters. Our ex vivo platform, which leverages our tumor bank to support large screening studies and assist our customers with their early preclinical work, is growing steadily. and David Barry. We have been excited with the enthusiasm and interest in our ex vivo product launch. This has contributed to our revenue growth and as we expand the ex vivo platform, we anticipate that it will be a great contributor to our overall growth in general. In addition, we continue in our R&D efforts to offer both new models for in vivo and ex vivo assays as well as to expand our biomarker endpoint analysis.
4:03 In summation, it was a strong quarter for the company as we saw the expected results of our strategies come to fruition. We are excited about the interest in our core services. as well as our expanded products, and we anticipate our revenue will continue to grow steadily. Now let me turn the call over to David Miller for the highlights of our financial results.
4:26 Thanks, Ronnie. Our full results on Form 10-Q will be filed with the SEC on or before March 16th. We had a strong quarter, kicking off the second half of our fiscal year with record revenue of $9 million and near-record net income. Our revenue increased by $2.6 million, or 40%, compared to the year-ago period. Excluding stock-based compound depreciation, we recognized a gain of approximately $900,000 compared to a gain of $91,000 in the year-ago period. Including stock-based compound depreciation, we recognized a gain of $430,000 for the quarter compared to a loss of $370,000 in the year-ago period. Focusing as we do on costs excluding stock-based comp and depreciation, our gross margin for the third quarter was 52% compared to 47% for the same period last year, with cost of sales increasing by $900,000.
5:23 It increases mainly attributed to the revenue growth and continued expansion of studies and process. R&D expense was approximately $1.4 million compared to $1.3 million in the year-ago period. We increased our R&D investment to continue growing our tumor bank along with expanding the capabilities of our in vivo and ex vivo platforms. This investment allows us to design and provide all of the tools to run increasingly complex studies. Sales and marketing expense was $1.2 million compared to $826,000 in the year-ago period. The increase was mainly due to compensation expense in the form of salaries and commissions. We expanded our business development team to penetrate deeper into existing territories as well as opening up new geographies and product lines.
6:10 Additionally, as discussed on our prior earnings call, we adjusted our methodology for accruing commissions by allocating these costs over the course of the year. Historically, commissions were heavily weighted into our fourth quarter. This accrual, combined with commissions earned on robust sales, contributed to the increase. Over the coming quarters, we intend to continue to grow our business development teams to capture more market share as well as explore other strategic opportunities. Our G&A expense was $1.2 million compared to $845,000 in the year-ago period. The increase is primarily due to higher salary expense along with approximately $150,000 in bad debt write-off. Let me be clear. Bad debt expense in our business is minimal, and this is not expected to be a recurring quarterly item. In total, our cash-based expenses were $8.1 million for the quarter, compared to $6.3 million in the same period last year, an increase of approximately $1.8 million, of which $900,000 was in cost of sales as a result of revenue growth and $400,000 in sales and marketing.
7:18 Now turning to cash. At the end of the third quarter, we had $3.3 million of cash on the balance sheet. For the quarter, cash used in operations was approximately breakeven, mainly due to the normal variability in the timing in accounts receivable and payable. with our anticipated revenue growth and profitability, we reiterate our cash flow operations will grow over the long term. Additionally, subsequent to the quarter end, we have added approximately $4 million, mostly the result of warrant exercises, solidifying our balance sheet with a cash balance of $7 million and no debt. Looking ahead to the remainder of fiscal year 2020, with the understanding that there's a bit of global uncertainty, We anticipate maintaining our profitability and we reiterate our year-over-year revenue guidance provided last quarter.
8:05 In summation, we had a record-breaking revenue quarter and we're very confident in the long-term prospects of the company. We look forward to our next call, which, because it's our year-end, will be at the end of July. We will now open the call to questions. At this time, we will be conducting a question-and-answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question today comes from Matt Hewitt of Craig Hallam. Please go ahead.
8:48 Good afternoon, gentlemen, and congratulations on the strong quarter.
8:52 Thank you very much, Matt.
8:55 First one, obviously on everybody's mind, I'm just curious what impact, if any, are you seeing from coronavirus? Maybe how is that impacting the start times from some studies or anything along those lines?
9:11 Yeah, so obviously it's first and foremost on our minds right now. We've been meeting regularly with the management team. As it stands right now, we are are all fully operational. We have sent all non-lab employees to work remotely just so that we won't have an increased risk of exposure to the other essential employees that work in the lab. We've increased our vigilance for hygiene and lab sterilization with more frequent cleanings and obviously all the other hygiene improvements that we've been able to do. We are closely monitoring the situation.
10:00 It's hard to know what the full exposure is, Matt. Obviously, things change on a daily basis. As it stands right now, we haven't seen a letdown in our bookings, and as long as we can keep our lab healthy, we have ordered a couple of A couple of months of supplies in advance, so in case there's a supply chain issue, we're well compensated for that. But what we're really monitoring is just the extent of the spread of the disease and whether it'll impact the operations of the workforce within our lab operations. And that's something we're monitoring. We're working very hard to reduce the risk of exposure.
10:48 But we'll only know in the next couple of weeks or months. There was one supplier of mice of ours that comes from China that impacted that. It wasn't a very large supplier, so it might impact revenue a little bit. But for the most part, up until now, we haven't been impacted. But it's just starting, so we'll have to keep you posted on that.
11:17 Along those lines, I'd seen some articles talking about the, I think it's, and correct me if I'm wrong, but the ACE2 mice and how those are in very short supply. I don't, correct me if I'm wrong, but I don't think you guys work with those types of mice, correct?
11:35 We don't, we don't, correct.
11:36 Okay. All right, well, thank you for the color on the virus. I guess shifting gears a little bit, you commented in the press release and then in your prepared remarks that regarding adding to the sales and business dev headcount. Where does that sit now and where do you see that going over the next year?
11:57 So over the last six months, we've roughly increased our headcount by about a third, about 30%. We feel like there's a lot of opportunity out there. and we feel like that we're going to continue increasing our business development headcount. So I don't know the exact number yet but we feel like there's an opportunity out there. We continue to grow our bookings and while we have an increase of demand and one of the things we've been doing as you know is we've also been increasing the products and the services so that also leads to a demand of needing more salespeople because we're doing more work and we're doing deeper work with more pharmaceutical companies.
12:46 So for the past six months, I'd say it's about 30%. That includes a bunch of geographies as well as just going deeper in the areas that we're currently at.
13:01 Got it. Okay, and then maybe last one and I'll hop back into queue. Thank you for the update on flow cytometry and the incremental color that you provided as far as Some of those pharma customers have come in, inspected. You're now on their approved list. Any additional code that you could provide as far as how frequently are those types of opportunities coming up for bid? Do you have any sense for how frequently that occurs and when? I know it's difficult, but when you might anticipate seeing some contracts being signed there? Thank you.
13:35 Yeah, it's, you know... I think to be fair and honest, we had already anticipated that we would have signed one or two studies. We are talking to a lot of groups. We are being seen as a favorable... I mean, at this point, there have been multiple pharma companies, as I said, who have come in and ordered us and talked to us and really like the work that they're seeing that we're doing. I think it's just a matter of timing. I... I don't know the exact timing. I believe very strongly that it will happen. I have a little less clarity on exactly the right timing. I do believe in the next couple months we will get our first signed contracts, but stay tuned for that.
14:26 Understood. Thank you. Once again, if you would like to ask a question, please press star then 1 on your telephone keypad. One moment, please, while we poll for questions. We do have a follow-up from Matt Hewitt of Craig Hallam. Please go ahead.
14:50 I'll keep going. As far as there was a mention of a small bad debt, non-recurring bad debt write-off, what was the amount of that during the quarter, David?
15:03 $150,000.
15:05 $150,000. Okay. Okay. That's great. And then I guess the last piece here, regarding as you add these new services and new market opportunities and you're adding some salespeople, how quickly are those new services translating into bookings and revenues? Are you able to flip the switch on those pretty quickly or... do they require some lead time? Maybe not to the extent of flow, but maybe they require a couple quarters before those orders start to flow.
15:41 Yeah, so I think it depends on the services that we have. So, for instance, one of the services that we currently have but we're making more robust and we plan to add in a bigger way is histology services. That's something that we currently do. Our partners, pharma customers and partners, utilized that. And that, once we roll out the more robust platform, probably the next couple of months, that we see almost an immediate impact. Ex vivo was similar. Once we had, you know, obviously the ex vivo platform is not just one assay. It's going to be multiple assays. But once we had one or two assays that were ready to go, the implementation and the execution was almost immediate, one or two quarters. When we talk about winning bids for clinical studies, I think it's just a longer period of time because we're attaching ourselves to a clinical trial. There's a lot more regulatory hurdles that we have to go through, and so there's a lot more auditing and investigating our capabilities.
16:55 And quite frankly, a lot of the companies had previous relationships. So in that respect, we were kind of breaking into a new area. Whereas in the preclinical space, when we add new services, and a lot of the new services that we're adding are just biomarker analytes or other ways that we can measure things within cells or expression levels. So those that come off a study, off a preclinical study, Those that we will be adding, we see a much quicker and a faster path to the commercial ability and revenue.
17:39 Understood. All right. Well, thank you for that, Collar.
17:44 Thanks, Matt. There are no additional questions at this time. I would like to turn the call back to Ronnie Morris for closing remarks.
17:53 Great, thank you. So I guess just to sum it up, we had a really nice quarter. We continue to be really excited about what's happening at Champions Oncology. We're building off an exciting platform with really exceptional people, great science, and we just are excited to continue this, and we look forward to talking to everybody on our next quarterly call. and in the meantime, hopefully by the time our next quarter new call comes out, the world will be in a more stable place. So appreciate it. Have a good evening, everybody. And we appreciate you coming on our call. Thank you. This concludes today's conference. You may disconnect your lines at this time.
18:41 Thank you for your participation.
18:43 The event playback has concluded. Thank you.
Follow Champions Oncology, Inc. into a list and get an email when it puts out news.
Chief Financial Officer
Chief Executive Officer
Analyst, Craig Hallam